Familial Systemic Mastocytosis With Germline Kit K509i Mutation Is Sensitive To Treatment With Imatinib, Dasatinib And Pkc412

dc.creatorde Melo Campos P.
dc.creatorMachado-Neto J.A.
dc.creatorScopim-Ribeiro R.
dc.creatorVisconte V.
dc.creatorTabarroki A.
dc.creatorDuarte A.S.S.
dc.creatorBarra F.F.C.
dc.creatorVassalo J.
dc.creatorRogers H.J.
dc.creatorLorand-Metze I.
dc.creatorTiu R.V.
dc.creatorCosta F.F.
dc.creatorOlalla Saad S.T.
dc.creatorTraina F.
dc.date2014
dc.date2015-06-25T18:02:27Z
dc.date2015-11-26T15:04:32Z
dc.date2015-06-25T18:02:27Z
dc.date2015-11-26T15:04:32Z
dc.date.accessioned2018-03-28T22:15:22Z
dc.date.available2018-03-28T22:15:22Z
dc.identifier
dc.identifierLeukemia Research. Elsevier Ltd, v. 38, n. 10, p. 1245 - 1251, 2014.
dc.identifier1452126
dc.identifier10.1016/j.leukres.2014.07.010
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84908024600&partnerID=40&md5=beaf055a96e0773ba38ebbf40f6a8203
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/87829
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/87829
dc.identifier2-s2.0-84908024600
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1256870
dc.descriptionMastocytosis are myeloproliferative neoplasms commonly related to gain-of-function mutations involving the tyrosine kinase domain of KIT. We herein report a case of familial systemic mastocytosis with the rare KIT K509I germ line mutation affecting two family members: mother and daughter. In vitro treatment with imatinib, dasatinib and PKC412 reduced cell viability of primary mast cells harboring KIT K509I mutation. However, imatinib was more effective in inducing apoptosis of neoplastic mast cells. Both patients with familial systemic mastocytosis had remarkable hematological and skin improvement after three months of imatinib treatment, suggesting that it may be an effective front line therapy for patients harboring KIT K509I mutation.
dc.description38
dc.description10
dc.description1245
dc.description1251
dc.descriptionGarcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients (2006) Blood, 108, pp. 2366-2372
dc.descriptionSanchez-Munoz, L., Alvarez-Twose, I., Garcia-Montero, A.C., Teodosio, C., Jara-Acevedo, M., Pedreira, C.E., Evaluation of the WHO criteria for the classification of patients with mastocytosis (2001) Mod Pathol, 24, pp. 1157-1168
dc.descriptionValent, P., Horny, H.P., Escribano, L., Longley, B.J., Li, C.Y., Schwartz, L.B., Diagnostic criteria and classification of mastocytosis: a consensus proposal (2001) Leuk Res, 25, pp. 603-625
dc.descriptionEscribano, L., Akin, C., Castells, M., Orfao, A., Metcalfe, D.D., Mastocytosis: current concepts in diagnosis and treatment (2002) Ann Hematol, 81, pp. 677-690
dc.descriptionValent, P., Akin, C., Sperr, W.R., Escribano, L., Arock, M., Horny, H.P., Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria (2003) Leuk Res, 27, pp. 635-641
dc.descriptionHorny, H., Metcalfe, D., Bennet, J., Bain, B., Akin, C., Escribano, L., Mastocytosis (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, pp. 54-63. , IARC Press, Lyon, S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman (Eds.)
dc.descriptionGeorgin-Lavialle, S., Lhermitte, L., Dubreuil, P., Chandesris, M.O., Hermine, O., Damaj, G., Mast cell leukemia (2013) Blood, 121, pp. 1285-1295
dc.descriptionPardanani, A., Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management (2013) Am J Hematol, 88, pp. 612-624
dc.descriptionFowler, J.F., Parsley, W.M., Cotter, P.G., Familial urticaria pigmentosa (1986) Arch Dermatol, 122, pp. 80-81
dc.descriptionClark, D.P., Buescher, L., Havey, A., Familial urticaria pigmentosa (1990) Arch Intern Med, 150, pp. 1742-1744
dc.descriptionOku, T., Hashizume, H., Yokote, R., Sano, T., Yamada, M., The familial occurrence of bullous mastocytosis (diffuse cutaneous mastocytosis) (1990) Arch Dermatol, 126, pp. 1478-1484
dc.descriptionAnstey, A., Lowe, D.G., Kirby, J.D., Horton, M.A., Familial mastocytosis: a clinical, immunophenotypic, light and electron microscopic study (1991) Br J Dermatol, 125, pp. 583-587
dc.descriptionChang, A., Tung, R.C., Schlesinger, T., Bergfeld, W.F., Dijkstra, J., Kahn, T.A., Familial cutaneous mastocytosis (2001) Pediatr Dermatol, 18, pp. 271-276
dc.descriptionHartmann, K., Wardelmann, E., Ma, Y., Merkelbach-Bruse, S., Preussner, L.M., Woolery, C., Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis (2005) Gastroenterology, 129, pp. 1042-1046
dc.descriptionWasag, B., Niedoszytko, M., Piskorz, A., Lange, M., Renke, J., Jassem, E., Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis (2011) Exp Hematol, 39. , 859-65 e2
dc.descriptionKunstlinger, H., Huss, S., Merkelbach-Bruse, S., Binot, E., Kleine, M.A., Loeser, H., Gastrointestinal Stromal tumors with KIT exon 9 mutations: update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing (2013) Am J Surg Pathol, 37, pp. 1648-1659
dc.descriptionZanotti, R., Simioni, L., Garcia-Montero, A.C., Perbellini, O., Bonadonna, P., Caruso, B., Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis (2013) J Allergy Clin Immunol, 131, pp. 605-607
dc.descriptionNing, Z.Q., Li, J., Arceci, R.J., Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells (2001) Blood, 97, pp. 3559-3567
dc.descriptionRottapel, R., Reedijk, M., Williams, D.E., Lyman, S.D., Anderson, D.M., Pawson, T., The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor (1991) Mol Cell Biol, 11, pp. 3043-3051
dc.descriptionLinnekin, D., Early signaling pathways activated by c-Kit in hematopoietic cells (1999) Int J Biochem Cell Biol, 31, pp. 1053-1074
dc.descriptionNagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y., Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder (1995) Proc Natl Acad Sci U S A, 92, pp. 10560-10564
dc.descriptionAkin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, B.J., Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit (2003) Exp Hematol, 31, pp. 686-692
dc.descriptionZermati, Y., De Sepulveda, P., Feger, F., Letard, S., Kersual, J., Casteran, N., Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms (2003) Oncogene, 22, pp. 660-664
dc.descriptionUstun, C., DeRemer, D.L., Akin, C., Tyrosine kinase inhibitors in the treatment of systemic mastocytosis (2011) Leuk Res, 35, pp. 1143-1152
dc.descriptionTraina, F., Visconte, V., Jankowska, A.M., Makishima, H., O'Keefe, C.L., Elson, P., Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis (2012) PLoS ONE, 7, p. e43090
dc.descriptionSchwaab, J., Schnittger, S., Sotlar, K., Walz, C., Fabarius, A., Pfirrmann, M., Comprehensive mutational profiling in advanced systemic mastocytosis (2013) Blood, 122, pp. 2460-2466
dc.descriptionTraina, F., Carvalheira, J.B., Saad, M.J., Costa, F.F., Saad, S.T., BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells (2003) FEBS Lett, 535, pp. 17-22
dc.descriptionAkin, C., Escribano, L., Nuñez, R., Garcia-Montero, A., Angulo, M., Orfao, A., Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations (2004) J Allergy Clin Immunol, 113, p. S327
dc.descriptionValent, P., Sotlar, K., Sperr, W.R., Escribano, L., Yavuz, S., Reiter, A., Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal (2014) Ann Oncol, , [Epub ahead of print]
dc.descriptionZhang, L.Y., Smith, M.L., Schultheis, B., Fitzgibbon, J., Lister, T.A., Melo, J.V., A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy (2006) Leuk Res, 30, pp. 373-378
dc.descriptionChan, E.C., Bai, Y., Kirshenbaum, A.S., Fischer, E.R., Simakova, O., Bandara, G., Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype (2014) J Allergy Clin Immunol, 134. , 178-87 e1
dc.descriptionPagano, L., Valentini, C.G., Caira, M., Rondoni, M., Van Lint, M.T., Candoni, A., Advanced mast cell disease: an Italian Hematological Multicenter experience (2008) Int J Hematol, 88, pp. 483-488
dc.descriptionSchittenhelm, M.M., Shiraga, S., Schroeder, A., Corbin, A.S., Griffith, D., Lee, F.Y., Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies (2006) Cancer Res, 66, pp. 473-481
dc.descriptionVerstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis (2008) Clin Cancer Res, 14, pp. 3906-3915
dc.descriptionGleixner, K.V., Mayerhofer, M., Aichberger, K.J., Derdak, S., Sonneck, K., Bohm, A., PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects (2006) Blood, 107, pp. 752-759
dc.descriptionFeng, L.X., Ravindranath, N., Dym, M., Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia (2000) J Biol Chem, 275, pp. 25572-25576
dc.descriptionGrowney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D., Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 (2005) Blood, 106, pp. 721-724
dc.descriptionRoberts, K.G., Odell, A.F., Byrnes, E.M., Baleato, R.M., Griffith, R., Lyons, A.B., Resistance to c-KIT kinase inhibitors conferred by V654A mutation (2007) Mol Cancer Ther, 6, pp. 1159-1166
dc.languageen
dc.publisherElsevier Ltd
dc.relationLeukemia Research
dc.rightsfechado
dc.sourceScopus
dc.titleFamilial Systemic Mastocytosis With Germline Kit K509i Mutation Is Sensitive To Treatment With Imatinib, Dasatinib And Pkc412
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución